Reduced Subvisible Particle Formation in Lyophilized Intravenous Immunoglobulin Formulations Containing Polysorbate 20.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Pharmacy and Science

• Publication date

  2016-08-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.xphs.2016.05.013PMID 27290624
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Stabilization of proteins in solid form.

  2015cited by this paper
• Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability

  2015cited by this paper
• Spray-Drying of Biopharmaceuticals

  2015cited by this paper
• Calculating the mass of subvisible protein particles with improved accuracy using microflow imaging data.

  2015cited by this paper
• Protein quantity on the air-solid interface determines degradation rates of human growth hormone in lyophilized samples.

  2014cited by this paper
• Storage stability of keratinocyte growth factor-2 in lyophilized formulations: effects of formulation physical properties and protein fraction at the solid-air interface.

  2014cited by this paper
• Stability of lyophilized sucrose formulations of an IgG1: subvisible particle formation

  2013cited by this paper
• Micro-flow imaging and resonant mass measurement (Archimedes)--complementary methods to quantitatively differentiate protein particles and silicone oil droplets.

  2013cited by this paper
• Challenges in Freeze–Thaw Processing of Bulk Protein Solutions

  2013cited by this paper
• Particles in therapeutic protein formulations, Part 1: overview of analytical methods.

  2012cited by this paper
• Quantification and characterization of micrometer and submicrometer subvisible particles in protein therapeutics by use of a suspended microchannel resonator.

  2012cited by this paper
• Characterization of subvisible particle formation during the filling pump operation of a monoclonal antibody solution.

  2011cited by this paper
• Subvisible particle counting provides a sensitive method of detecting and quantifying aggregation of monoclonal antibody caused by freeze-thawing: insights into the roles of particles in the protein aggregation pathway.

  2011cited by this paper
• Protein Aggregation and Particle Formation: Effects of Formulation, Interfaces, and Drug Product Manufacturing Operations

  2010cited by this paper
• Mechanisms of protein stabilization in the solid state.

  2009cited by this paper
• The impact of drying method and formulation on the physical properties and stability of methionyl human growth hormone in the amorphous solid state.

  2008cited by this paper
• Drying-induced variations in physico-chemical properties of amorphous pharmaceuticals and their impact on stability (I): stability of a monoclonal antibody.

  2007cited by this paper
• Mechanism of protein stabilization by sugars during freeze-drying and storage: native structure preservation, specific interaction, and/or immobilization in a glassy matrix?

  2005cited by this paper
• Effects of annealing lyophilized and spray-lyophilized formulations of recombinant human interferon-gamma.

  2003cited by this paper
• A new mechanism for decreasing aggregation of recombinant human interferon-gamma by a surfactant: slowed dissolution of lyophilized formulations in a solution containing 0.03% polysorbate 20.

  2002cited by this paper
• Rational design of stable lyophilized protein formulations: theory and practice.

  2002cited by this paper
• Surface adsorption of recombinant human interferon-gamma in lyophilized and spray-lyophilized formulations.

  2002cited by this paper
• Lyophilization-induced protein denaturation in phosphate buffer systems: monomeric and tetrameric beta-galactosidase.

  2001cited by this paper
• Factors affecting short-term and long-term stabilities of proteins.

  2001cited by this paper
• A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibody.

  2001cited by this paper
• Annealing to optimize the primary drying rate, reduce freezing-induced drying rate heterogeneity, and determine T(g)' in pharmaceutical lyophilization.

  2001cited by this paper
• Crystal Structure of a Neutralizing Human IgG Against HIV-1: A Template for Vaccine Design

  2001cited by this paper
• Lyophilization and development of solid protein pharmaceuticals.

  2000cited by this paper
• Protein formulation and lyophilization cycle design: prevention of damage due to freeze-concentration induced phase separation.

  1999cited by this paper
• TM-AFM Threshold Analysis of Macromolecular Orientation: A Study of the Orientation of IgG and IgE on Mica Surfaces.

  1998cited by this paper
• Rational Design of Stable Lyophilized Protein Formulations: Some Practical Advice

  1997cited by this paper
• Polymers protect lactate dehydrogenase during freeze-drying by inhibiting dissociation in the frozen state.

  1996cited by this paper
• The Effect of the Reconstitution Medium on Aggregation of Lyophilized Recombinant Interleukin-2 and Ribonuclease A

  1996cited by this paper
• Proteins in frozen solutions: evidence of ice-induced partial unfolding.

  1996cited by this paper
• Surface-induced denaturation of proteins during freezing and its inhibition by surfactants.

  1996cited by this paper
• Stabilizing effect of amphiphilic excipients on the freeze‐thawing and freeze‐drying of lactate dehydrogenase

  1994cited by this paper
• Freezing denaturation of ovalbumin at acid pH.

  1990cited by this paper

• Impact of Initial Aggregate Level on Aggregation Potential of Monoclonal Antibodies in Different Buffer Systems

  2025cites this paper
• EVALUATING THE STORAGE STABILITY OF A Plasmodium vivax CIRCUMSPOROZOITE PROTEIN VACCINE CANDIDATE

  2025cites this paper
• Protein microbeadification to achieve highly concentrated protein formulation with reversible properties and in vivo pharmacokinetics after reconstitution.

  2021cites this paper
• Review of the current state of protein aggregation inhibition from a materials chemistry perspective: special focus on polymeric materials

  2021cites this paper
• Subvisible Particle Analysis of 17 Monoclonal Antibodies Approved in China Using Flow Imaging and Light Obscuration.

  2021cites this paper
• Frontiers in Protein Structure, Function, and Dynamics

  2020cites this paper
• Aggregation and Particle Formation During Pumping of an Antibody Formulation are Controlled by Electrostatic Interactions between Pump Surfaces and Protein Molecules.

  2020cites this paper
• Rational design to biologics development: the polysorbates point of view.

  2020cites this paper
• Development and validation of a selective marker-based quantification of polysorbate 20 in biopharmaceutical formulations using UPLC QDa detection.

  2020cites this paper
• Management of Insulin Through Co-Solute Engineering: A Therapeutic Approach

  2020cites this paper
• Characterization of Subvisible Particles in Biotherapeutic Pre-Filled Syringes: The Role of Polysorbate and Protein on the Formation of Silicone Oil and Protein Subvisible Particles After Drop Shock.

  2019cites this paper
• Accelerated Aggregation Studies of Monoclonal Antibodies: Considerations for Storage Stability.

  2019cites this paper
• Science and Art of Protein Formulation Development.

  2019cites this paper
• Polysorbate degradation in biotherapeutic formulations: Identification and discussion of current root causes

  2018cites this paper
• Protein aggregation - Mechanisms, detection, and control.

  2018cites this paper
• Some Lessons Learned From a Comparison Between Sedimentation Velocity Analytical Ultracentrifugation and Size Exclusion Chromatography to Characterize and Quantify Protein Aggregates.

  2017cites this paper